Market Cap 1.62B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 2,502,864
Avg Vol 7,121,714
Day's Range N/A - N/A
Shares Out 305.38M
Stochastic %K 26%
Beta 1.14
Analysts Strong Sell
Price Target $10.50

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
Rastafari
Rastafari Jul. 30 at 6:20 PM
$ABCL hopefully we get to extend partnerships with this list of current partners (similar to Jazz/Vertex) Eli Lilly and Company collaboration in immunology, cardiovascular disease, neuroscience, and COVID-19 antibodies AbbVie Multi-target oncology antibody discovery partnership. Biogen Neuroscience-focused antibody discovery collaboration. Novartis Antibody discovery partner. Regeneron Pharmaceuticals Discovery collaboration. Incyte Therapeutic antibody partner. Gilead Sciences Antibody discovery collaboration. Denali Therapeutics Neurology programs, including Alzheimer’s disease. Teva Pharmaceutical Industries Neuroscience antibody program. Abdera Therapeutics Radiopharmaceutical oncology collaboration. Prelude Therapeutics Listed strategic partner. Empirico Target discovery and antibody development collaboration.
0 · Reply
DeMampCamp
DeMampCamp Jul. 30 at 4:48 PM
$ABCL The AbCellera that we all know! Gets slaughtered with the overall market takedown, but red when there's a slight recovery day, all you can do is just laugh and then close the brokerage app! Have a great day everyone!
1 · Reply
PolarBear1
PolarBear1 Jul. 30 at 4:09 PM
$ABCL I expect next Wednesday’s Q2 results to be good and reflect some of the Jazz upfronts and reiterate the number from Vertex they received in July deal but very little about 635 Phase 2 topline. I expect them to release that PR the 2nd or 3rd week of September. I also expect more materially positive news about current/new partnership developments by the end of September. If 635 positive then the shorts will get blown away (quite rightly) and we should see close to $10 ps by the end of 2026 just in time for a material announcement on results/partnering on AD product by January 2027 in time for 45th JP Morgan Healthcare conference in SFO w/b January 11th.
1 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 30 at 3:33 PM
$ABCL Both the Jazz and the Vertex deal give $ABCL the option to run cell line development, process development and clinical manufacturing through Phase 1. That is what turns the Vancouver plant from a cost centre into a second revenue line.
0 · Reply
tradersunion353
tradersunion353 Jul. 30 at 3:32 PM
$ABCL market is sharply up even a penny BS stocks are up sharply Meanhile overhyped junk is about to go red. what are you clowns celebrating for?
0 · Reply
tradersunion353
tradersunion353 Jul. 30 at 3:07 PM
$ABCL MArried to ABCL folks and paper trader At 8,5,6,5,4,3,2,1. with adding and loading comments they just dont care if this POS goes to zero -- they just want to add.
1 · Reply
tradersunion353
tradersunion353 Jul. 30 at 2:52 PM
$ABCL Clowns market is sharply up meanwhile ABCL overhyped junk ilost 40% in 2 weeks How is that adding and loading and gift from heaven adding at at 8,7,6,5 working 🤣
1 · Reply
Vogelito
Vogelito Jul. 30 at 2:26 PM
$ABCL @tradersunion353 How come you are quiet on green days for $ABCL ? Obviously the day is far from over but your silence speaks a thousand words
1 · Reply
Stockingtrade
Stockingtrade Jul. 30 at 2:05 PM
$ABCL Price is up, on increased volume, for third day running. Here we go!!
0 · Reply
Ckkung71
Ckkung71 Jul. 30 at 1:59 PM
$ABCL Stay away from shorters flipping just buy and hold😎
0 · Reply
Latest News on ABCL
AbCellera upgraded to Buy from Hold at Benchmark

2026-07-07T10:35:14.000Z - 23 days ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ


AbCellera apponts Lynn Seely to board of directors

2026-07-06T13:15:29.000Z - 24 days ago

AbCellera apponts Lynn Seely to board of directors

LYEL


AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jul 6, 2026, 9:00 AM EDT - 24 days ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors


AbCellera appoints Victor Sandor to board of directors

2026-06-05T13:05:56.000Z - 7 weeks ago

AbCellera appoints Victor Sandor to board of directors


AbCellera price target raised to $8 from $7 at Stifel

2026-05-12T10:58:11.000Z - 2 months ago

AbCellera price target raised to $8 from $7 at Stifel


AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026


AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Earnings release: Q1 2026


AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Quarterly report: Q1 2026


AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Slides: Q1 2026


AbCellera initiated with an Overweight at Cantor Fitzgerald

2026-05-05T10:36:31.000Z - 3 months ago

AbCellera initiated with an Overweight at Cantor Fitzgerald


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera initiated with a Buy at JonesResearch

2026-04-09T20:10:26.000Z - 3 months ago

AbCellera initiated with a Buy at JonesResearch


AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025


AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Annual report: Q4 2025


AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Earnings release: Q4 2025


AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Slides: Q4 2025


AbCellera reports FY25 EPS (49c) vs. (55c) last year

2026-02-24T21:15:21.000Z - 5 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year


AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 5 months ago

AbCellera Reports Full Year 2025 Business Results


AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 7 months ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 9 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors


AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025


AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Quarterly report: Q3 2025


AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Earnings release: Q3 2025


AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Slides: Q3 2025


AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 9 months ago

AbCellera Reports Q3 2025 Business Results


AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 11 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer


AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2025


AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2025


AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2025


AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2025


AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation


AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025


AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025


AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025


AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025


AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024


AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024


AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024


AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024


AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results


AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025


AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024


AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024


AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024


AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024


AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q2 2024


AbCellera Biologics Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q2 2024


AbCellera Biologics Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q2 2024


AbCellera Biologics Slides: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q2 2024


AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q2 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024


AbCellera Biologics Quarterly report: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q1 2024


AbCellera Biologics Earnings release: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q1 2024


AbCellera Biologics Slides: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q1 2024


AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results


Rastafari
Rastafari Jul. 30 at 6:20 PM
$ABCL hopefully we get to extend partnerships with this list of current partners (similar to Jazz/Vertex) Eli Lilly and Company collaboration in immunology, cardiovascular disease, neuroscience, and COVID-19 antibodies AbbVie Multi-target oncology antibody discovery partnership. Biogen Neuroscience-focused antibody discovery collaboration. Novartis Antibody discovery partner. Regeneron Pharmaceuticals Discovery collaboration. Incyte Therapeutic antibody partner. Gilead Sciences Antibody discovery collaboration. Denali Therapeutics Neurology programs, including Alzheimer’s disease. Teva Pharmaceutical Industries Neuroscience antibody program. Abdera Therapeutics Radiopharmaceutical oncology collaboration. Prelude Therapeutics Listed strategic partner. Empirico Target discovery and antibody development collaboration.
0 · Reply
DeMampCamp
DeMampCamp Jul. 30 at 4:48 PM
$ABCL The AbCellera that we all know! Gets slaughtered with the overall market takedown, but red when there's a slight recovery day, all you can do is just laugh and then close the brokerage app! Have a great day everyone!
1 · Reply
PolarBear1
PolarBear1 Jul. 30 at 4:09 PM
$ABCL I expect next Wednesday’s Q2 results to be good and reflect some of the Jazz upfronts and reiterate the number from Vertex they received in July deal but very little about 635 Phase 2 topline. I expect them to release that PR the 2nd or 3rd week of September. I also expect more materially positive news about current/new partnership developments by the end of September. If 635 positive then the shorts will get blown away (quite rightly) and we should see close to $10 ps by the end of 2026 just in time for a material announcement on results/partnering on AD product by January 2027 in time for 45th JP Morgan Healthcare conference in SFO w/b January 11th.
1 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 30 at 3:33 PM
$ABCL Both the Jazz and the Vertex deal give $ABCL the option to run cell line development, process development and clinical manufacturing through Phase 1. That is what turns the Vancouver plant from a cost centre into a second revenue line.
0 · Reply
tradersunion353
tradersunion353 Jul. 30 at 3:32 PM
$ABCL market is sharply up even a penny BS stocks are up sharply Meanhile overhyped junk is about to go red. what are you clowns celebrating for?
0 · Reply
tradersunion353
tradersunion353 Jul. 30 at 3:07 PM
$ABCL MArried to ABCL folks and paper trader At 8,5,6,5,4,3,2,1. with adding and loading comments they just dont care if this POS goes to zero -- they just want to add.
1 · Reply
tradersunion353
tradersunion353 Jul. 30 at 2:52 PM
$ABCL Clowns market is sharply up meanwhile ABCL overhyped junk ilost 40% in 2 weeks How is that adding and loading and gift from heaven adding at at 8,7,6,5 working 🤣
1 · Reply
Vogelito
Vogelito Jul. 30 at 2:26 PM
$ABCL @tradersunion353 How come you are quiet on green days for $ABCL ? Obviously the day is far from over but your silence speaks a thousand words
1 · Reply
Stockingtrade
Stockingtrade Jul. 30 at 2:05 PM
$ABCL Price is up, on increased volume, for third day running. Here we go!!
0 · Reply
Ckkung71
Ckkung71 Jul. 30 at 1:59 PM
$ABCL Stay away from shorters flipping just buy and hold😎
0 · Reply
Kaykay610
Kaykay610 Jul. 30 at 1:39 PM
$ABCL https://youtu.be/xlLTlChs64M?is=KoboH4Ss2kJl7ewl TS: (59:43) Don't forget Abcl is the star that the Canadian gov is building around
0 · Reply
DanielWarren199
DanielWarren199 Jul. 30 at 12:42 PM
The new $ABCL collaboration looks meaningful. The upfront payment doesn't tell the whole story. Milestones and royalties are where the real value could show up. Too many unknowns to guess the payout today. I'm happy to own it. Now they have to execute.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 30 at 10:31 AM
$ABCL $ABCL AbCellera just signed a partnership with Vertex Pharmaceuticals, one of the most respected drug companies in the world (~$100B market cap, known for their cystic fibrosis franchise and increasingly for autoimmune disease). Vertex is hiring AbCellera's technology platform to discover a specific type of drug called T-cell engagers (TCEs) for autoimmune diseases. Think of it like this: Vertex is the client, AbCellera is the specialized contractor. Vertex says "we want to build these drugs but your tools are better than ours for this particular job." AbCellera does the early discovery and engineering work, Vertex funds everything and takes the drugs through late-stage trials and commercialization.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 30 at 10:31 AM
$ABCL AbCellera gets $28M upfront, plus milestone payments if the drugs hit development targets, regulatory approvals, and commercial sales, plus royalties on any eventual product revenue. They may also get paid separately to handle manufacturing through Phase 1 trials. Three things stand out. First, partner quality. Vertex is not a speculative biotech. They are one of the most disciplined drug developers in the industry. They don't sign deals casually. Having Vertex validate your TCE platform alongside the recent Jazz Pharmaceuticals deal ($56M upfront for oncology TCEs) is a pattern, not a one-off. Two major pharma companies independently choosing your platform within months of each other is the strongest form of technology validation.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 30 at 10:30 AM
$ABCL Second, therapeutic expansion. The Jazz deal was oncology. This deal is autoimmune disease. That means AbCellera's TCE platform is being recognized as versatile enough to work across multiple disease areas, which dramatically expands the addressable market. Autoimmune is a massive therapeutic category (think rheumatoid arthritis, lupus, MS, etc.). Third, economics. AbCellera bears zero R&D cost on these programs. Vertex pays for everything. AbCellera gets paid upfront, gets paid at milestones, and gets royalties if anything reaches patients. It is a capital-light model where upside accrues without AbCellera having to fund expensive clinical trials. Macro is noisy today, but this deal is as clear a signal as any investor could possibly hope for.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 30 at 8:49 AM
$ABCL $ABCL - interesting relative strength and holding bullish posture $IBB $ARKG $XBI
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 30 at 6:02 AM
$ABCL Another example of the $ABCL team showing and not telling through a partnership with $VRTX , only about a month after the $JAZZ collaboration ($56 million in upfront fees) focused on Next-Generation T-Cell Anditbody discovery. $ABCL receives $28 million in total upfront payments from $VRTX and is eligible to receive milestone payments and tiered royalties on net sales. Exciting times. "Vertex is committed to transforming the treatment landscape for people with serious diseases,” said Mark Bunnage, D.Phil., EVP and Chief Scientific Officer at Vertex. “AbCellera’s T-cell engager platform offers sophisticated capabilities for discovering and engineering multispecific antibodies and we look forward to working with AbCellera’s team to explore the potential of this technology to develop innovative therapies for patients in need."
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 30 at 5:26 AM
$ABCL 🗣️ Carl Hansen CEO: "We are excited to collaborate with Vertex, a recognized leader in innovation, to accelerate the development of new, transformative therapies."
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 30 at 4:38 AM
$ABCL If you use log scale (more appropriate), there was a breakout on $ABCL today
0 · Reply
Stockholde
Stockholde Jul. 30 at 4:29 AM
$ABCL the kind of partnerships show potential to be a multi billion dollar company potentially in 200 billion plus thw risk reward is insane at this price
0 · Reply
Rastafari
Rastafari Jul. 30 at 1:15 AM
$ABCL a few things to understand on next weeks earnings call: 1. How much of the upfront payments was recognized as Q2 revenue. 2. How much was recorded as deferred revenue to be recognized in future quarters. 3. Management’s guidance on expected milestone payments and future royalty potential If anyone has any thoughts, would love to hear.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 30 at 12:06 AM
$ABCL $ABCL picked the worst possible day to announce bullish news, with $QQQ down 2%. And yet, it still closed green. The market may keep disrespecting $ABCL for now but don’t worry. Our time to shine will come.
0 · Reply